biotech / news / / CNBC
Novartis, Amgen and Eli Lilly are in late-stage trials to test whether drugs that cut Lp(a) can protect people from heart attacks.
Novartis, Amgen, and Lilly are in late-stage trials testing drugs to lower Lp(a) cholesterol.
KEY POINTS
- Novartis' Phase 3 readout of pelacarsen, expected mid-2024, will be the first clinical outcome data.
- All three companies proved their drugs cut Lp(a) by over 80%, but clinical benefit remains unproven.
- Less than 1% of U.S. adults were tested for Lp(a) in 2024, despite new screening recommendations.
- Lilly is developing both a daily pill and a gene-editing treatment to target Lp(a) reduction.
COMPANIES
Summarized by Newsio from CNBC. How we summarize →